ArticleJournal of travel medicine2024
Epidemiology of travel-associated dengue from 2007 to 2022: A GeoSentinel analysis.
Article in Journal of travel medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Dengue among immunocompromised patients: a systematic review and meta-analysis.Journal of travel medicine · 2025Pooled it
- Safety and immunogenicity of a tetravalent dengue vaccine (CYD-TDV) in HIV-positive adults aged 18-50 years in Brazil: Results from a phase II, randomized, observer-blind, placebo-controlled trial.Human vaccines & immunotherapeutics · 2025Trial
- Cross-national prediction of imported dengue risk in Northeast Asia using climate, hydrological, and viral epidemiological indicators.Tropical medicine and health · 2026Article
- Assessment of the healthcare burden of dengue disease in England: a retrospective analysis (2010-2023).Journal of travel medicine · 2026Article
- Shared evidence, different recommendations: a comparative analysis of Qdenga (TAK-003) dengue vaccine guidance for travellers across countries.Journal of travel medicine · 2026Article
- Safety of the Dengue Vaccine TAK-003 and Factors Associated with Adverse Events in Travellers from Non-Endemic Areas: A Real-World Prospective Multicentre Pharmacovigilance Cohort Study in Spain.The Lancet regional health. Europe · 2026Article
- Global, Regional, and National Burden of Malaria and Dengue from 1992 to 2021, with Projections to 2036: An Age-Period-Cohort Analysis.Tropical medicine and infectious disease · 2026Article
- Assessment of the healthcare burden of dengue disease in Germany: a retrospective analysis of statutory health insurance data (2014-23).Journal of travel medicine · 2026Article
- Anti-Dengue IgG Seroprevalence and Exposure-Related Risk in Italian Military Personnel Deployed on Overseas Missions: A Cross-Sectional Study.Tropical medicine and infectious disease · 2026Article
- Causal inference for targeted public health interventions: interactions among environmental, social, and economic determinants within the one health framework.Journal of water and health · 2026Review
- Increase in Travel-Associated and Locally Acquired Dengue Cases - United States, 2024.MMWR. Morbidity and mortality weekly report · 2026Article
- Optimizing dengue vaccination strategies.PLoS medicine · 2026Review
- The TAK-003 story: key decisions that shaped development of a tetravalent dengue vaccine.NPJ vaccines · 2026Review
- Dengue and severe dengue.Clinical microbiology reviews · 2025Review
- The burden of dengue fever in travellers: a systematic literature review.New microbes and new infections · 2025Review
- Incidence, Duration, and Risk Factors for Diagnostic Delays Associated with Dengue: A Population-Based Study.The American journal of tropical medicine and hygiene · 2025Article
- A framework to assess the risk of yellow fever emergence.Journal of travel medicine · 2025Article
- Imported Dengue Fever in Milan, Italy: A Seven-Year Retrospective Study.Infectious disease reports · 2025Article
- Increase of Dengue in Pediatric Travelers in Madrid: A Multicentric Retrospective Experience.Tropical medicine and infectious disease · 2025Article
- Susceptibility ofInsects · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
Abstract
backgroundDengue is a leading cause of febrile illness among international travellers. We aimed to describe the epidemiology and clinical characteristics of imported dengue in returning travellers evaluated at GeoSentinel sites from 2007 to 2022.
methodsWe retrieved GeoSentinel records of dengue among travellers residing in non-endemic countries. We considered dengue confirmed when diagnosed by a positive dengue virus (DENV)-specific reverse-transcriptase polymerase chain reaction, positive NS-1 antigen and/or anti-DENV IgG seroconversion, and probable when diagnosed by single anti-DENV IgM or high-titre anti-DENV IgG detection. Severe dengue was defined as evidence of clinically significant plasma leakage or bleeding, organ failure, or shock, according to the 2009 World Health Organization guidance. Complicated dengue was defined as either severe dengue or dengue with presence of any warning sign. Analyses were descriptive.
resultsThis analysis included 5958 travellers with confirmed (n = 4859; 81.6%) or probable (n = 1099; 18.4%) dengue. The median age was 33 years (range: <1-91); 3007 (50.5%) travellers were female. The median travel duration was 21 days (interquartile range [IQR]: 15-32). The median time between illness onset and GeoSentinel site visit was 7 days (IQR: 4-15). The most frequent reasons for travel were tourism (67.3%), visiting friends or relatives (12.2%) and business (11.0%). The most frequent regions of acquisition were South East Asia (50.4%), South Central Asia (14.9%), the Caribbean (10.9%) and South America (9.2%). Ninety-five (1.6%) travellers had complicated dengue, of whom 27 (0.5%) had severe dengue and one died. Of 2710 travellers with data available, 724 (26.7%) were hospitalized. The largest number of cases (n = 835) was reported in 2019.
conclusionsA broad range of international travellers should be aware of the risk of acquiring dengue and receive appropriate pre-travel counselling regarding preventive measures. Prospective cohort studies are needed to further elucidate dengue risk by destination and over time, as well as severe outcomes and prolonged morbidity (long dengue) due to travel-related dengue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.